Enliven Therapeutics (ELVN) Current Leases (2021 - 2026)
Enliven Therapeutics (ELVN) reported Current Leases of $302000.0 for Q1 2026, down 17.26% on a YoY basis from $365000.0 in Q1 2025, and down 24.31% sequentially from $399000.0 in Q4 2025.
Enliven Therapeutics (ELVN) Current Leases (2021 - 2026) Analysis & Trends
Enliven Therapeutics (ELVN) has 6 years of Current Leases data on file, last reported at $302000.0 in Q1 2026.
- For the quarter ending Q1 2026, Current Leases fell 17.26% year-over-year to $302000.0; the trailing twelve-month figure through Mar 2026 stood at $302000.0 (down 17.26% YoY), and the FY2025 full-year result was $399000.0, changed N/A from the prior year.
- Current Leases eased to $302000.0 in Q1 2026, from $399000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $508000.0 in Q1 2022 to a low of $85000.0 in Q3 2024.
- A 5-year average of $329071.4 and a median of $333500.0 in 2023 frame the typical range for Current Leases.
- Across the five-year window, Current Leases slumped 74.4% in 2024 and jumped 355.29% in 2025, its largest moves.
- Tracing ELVN's Current Leases over 5 years: stood at $323000.0 in 2022, then increased by 3.72% to $335000.0 in 2023, then tumbled by 74.63% to $85000.0 in 2024, then soared by 369.41% to $399000.0 in 2025, then slipped by 24.31% to $302000.0 in 2026.
- Business Quant data shows ELVN's Current Leases at $302000.0 in Q1 2026, $399000.0 in Q4 2025, and $387000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 531,233.95 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 20.58 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 872,589.03 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 720.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 11.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.61 Mn |
| 10 | Enliven Therapeutics | 3.22 Bn | 3.22 Bn | - | 302,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 302,000.00 |
| Dec 31, 2025 | 399,000.00 |
| Sep 30, 2025 | 387,000.00 |
| Jun 30, 2025 | 376,000.00 |
| Mar 31, 2025 | 365,000.00 |
| Sep 30, 2024 | 85,000.00 |
| Jun 30, 2024 | 169,000.00 |
| Mar 31, 2024 | 252,000.00 |
| Dec 31, 2023 | 335,000.00 |
| Sep 30, 2023 | 332,000.00 |
| Jun 30, 2023 | 329,000.00 |
| Dec 31, 2022 | 323,000.00 |
| Jun 30, 2022 | 445,000.00 |
| Mar 31, 2022 | 508,000.00 |
| Dec 31, 2021 | 246,000.00 |
| Sep 30, 2021 | 250,000.00 |
| Jun 30, 2021 | 254,000.00 |
| Mar 31, 2021 | 257,000.00 |